**Conflict of interest**

The authors declare that they have no conflict of interest.

[3] Cornelius AJ, Chambers S, Aitken J, et al. Epsilonproteobacteria in humans, New

Clinical Manifestations of the *Epsilonproteobacteria* (*Helicobacter pylori*)

http://dx.doi.org/10.5772/intechopen.80331

[4] Maher M, Finnegan C, Collins E, et al. Evaluation of culture methods and a DNA probebased PCR assay for detection of *Campylobacter* species in clinical specimens of feces.

[5] Cover TL, Blaser MJ. *Helicobacter pylori* in health and disease. Gastroenterology. 2009;

[6] Andersen LP. New *Helicobacter* species in humans. Digestive Diseases. 2001;**19**(2):112-115 [7] Andersen LP. Colonization and infection by *Helicobacter pylori* in Humans. Helicobacter.

[8] Mobley HLT. *Helicobacter pylori* Factors associated with disease development. Gastro-

[9] Andersen LP, Boye K, Blom J, et al. Characterization of a culturable "*Gastrospirillum hominis"* (*Helicobacter heilmannii*) strain isolated from human gastric mucosa. Journal of

[11] Holck S, Ingeholm P, Blom J, et al. The histopathology of human gastric mucosa inhabited by *Helicobacter heilmannii* -like (*Gastrospirillum hominis*) organisms, including the first culturable case. Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 1997;

[12] Kobayashi M, Lee H, Nakayama J, et al. Roles of gastric mucin-type O-glycans in the pathogenesis of *Helicobacter pylori* infection. Glycobiology. 2009;**19**(5):453-461

[13] Chmiela M, Gonciarz W. Molecular mimicry in *Helicobacter pylori* infections. World

[14] Vial T, Descotes J.Autoimmune diseases and vaccinations. European Journal of Dermato-

[15] McCoy L, Tsunoda I, Fujinami RS. Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by

[16] Ram M, Shoenfeld Y. Hepatitis B: Infection, vaccination and autoimmunity. IMAJ. 2008;

[17] Ravel G, Christ M, Horand F, et al. Autoimmunity, environmental exposure and vac-

[18] Smyk DS, Koutsoumpas AL, Mytilinaiou MG, et al. *Helicobacter pylori* and autoimmune disease: Cause or bystander. World Journal of Gastroenterology. 2014;**20**(3):613-629 [19] Hagymási K, Tulassay Z. *Helicobacter pylori* infection: New pathogenetic and clinical

[20] Malfertheiner P, Michetti P, Price A. *Helicobacter pylori*: An Atlas. 1st ed. Science Press;

Zealand. Emerging Infectious Diseases. 2012;**18**(3):510-512

Journal of Clinical Microbiology. 2003;**41**(7):2980-2986

**136**(6):1863-1873

2007;**12**(s2):12-15

**105**(7-12):746-756

logy. 2004;**14**(2):86-90

**10**:61-64

1996

enterology. 1997;**113**(6):S21-S28

Clinical Microbiology. 1999;**37**(4):1069-1076

[10] Kim N. *Helicobacter pylori*. Springer Singapore: Singapore; 2016

Journal of Gastroenterology. 2017;**23**(22):3964-3977

bystander activation. Autoimmunity. 2006;**39**(1):9-19

cination: Is there a link? Toxicology. 2004;**196**(3):211-216

aspects. World Journal of Gastroenterology. 2014;**20**(21):6386-6399
